News

Historically, surgeons performed phacoemulsification with a straight-tip handpiece.

Want to jazz up your office and make a little extra profit at the same time? Read on.

Expert discusses the ways in which the AAO can help ophthalmologists survive and thrive in an uncertain economy.

The results of the 2010 Ophthalmology Times Best Programs survey show very few differences from last year despite advances and growth within ophthalmology departments across the United States.

If accessories are not part of your sales strategy, it's time to revisit that decision and explore the myths and realities of this category.

Results from a series of bench studies conducted under strictly controlled conditions consistently indicate that torsional phacoemulsification generates less heat at the incision site than longitudinal phaco.

The author discusses how policies can get in the way of good medicine.

Ongoing development of increasingly customized IOLs provides an ophthalmic surgeon with the means to offer refractive cataract surgery patients a lens or a combination of complementary lenses that specifically address their individual needs.

Some patients who have had previous wavefront-optimized laser vision correction present with quality-of-vision complaints, such as halo and glare, despite having 20/20 visual acuity.

Bilateral implantation of a three-piece aspheric diffractive multifocal IOL with refractive enhancement as needed provides excellent visual outcomes for a broad range of patients seen in real-world clinical practice.

A study evaluating outcomes in eyes undergoing LASIK for >-4 D of myopia reaffirms the established efficacy, safety and predictability of treatments performed with the wavefront-optimized, wavefront-guided and topography-guided ablation profiles of an excimer laser.

Throughout the eye department at Duke, faculty, residents, fellows and scientists work to further the understanding of eye disease and discover potential treatments.

Patients who have undergone cataract surgery with the +3-D add version of the apodized diffractive aspheric multifocal IOL implanted bilaterally demonstrate a significant postoperative improvement in perceived driving ability.

Providing appropriate amount of care to each patient is important.

The American Medical Association (AMA) has published a new Current Procedural Terminology (CPT) code that applies to a proprietary osmolarity test (TearLab).

Eyetech Inc. has entered into a licensing and development agreement with SurModics Pharmaceuticals Inc. to develop an extended-release version of pegaptanib sodium injection (Macugen) using microparticle technology.

The FDA has cleared a new, age-adjusted retinal nerve fiber layer thickness normative database for a proprietary ocular coherence tomography (OCT) device (Spectralis, Heidelberg Engineering GmbH).

The FDA has approved a supplemental new drug application for a once-daily bromfenac 0.09% ophthalmic solution (Bromday [formerly called XiDay], ISTA Pharmaceuticals) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

The FDA has cleared a new-generation multipurpose disinfecting solution (RevitaLens Ocutec, Abbott Medical Optics [AMO]) for silicone hydrogel and conventional soft contact lenses.

A new lubricant eye drop (Systane Balance, Alcon Laboratories) has been launched for patients with meibomian gland dysfunction.

About 23,000 people attended this year?s American Academy of Ophthalmology (AAO) annual meeting in Chicago, according to the organization.

A new lubricant eye drop offers a new treatment option for patients with meibomian gland dysfunction.

A dexamethasone intravitreal implant is a notable new therapeutic option for eyes with macular edema secondary to branch retinal vein occlusion or central retinal vein occlusion and may reduce the risk of vision loss as well as improve both the speed and incidence of visual improvement, according to one expert.

A new combined vitrectomy and phacoemulsification system was created to provide advanced technology for vitreoretinal and cataract procedures in a single, compact platform.

Analyses of data collected through 24 months of follow-up in a phase II, prospective, multicenter clinical trial support the conclusion that vascular endothelial growth factor blockade with ranibizumab is beneficial for the treatment of diabetic macular edema.

Primary readout results from 24 months of follow-up in the pivotal phase III fluocinolone acetonide in diabetic macular edema studies demonstrate that a novel investigational corticosteroid-releasing intravitreal insert provides rapid and sustained improvement in visual acuity and macular swelling with an acceptable safety profile.

Despite having a variety of imaging and treatment technologies available for retinal disease management, each technology has inherent properties that define its limitations. Integration of combinations of these technologies promises to be the best remedy for these individual shortcomings and may help achieve optimal outcomes.

Phase II study data indicate that pegaptanib sodium injection is an effective and safe treatment for diabetic macular edema.

Epimacular brachytherapy seems to be a safe and effective approach for treating neovascular age-related macular degeneration based on the 36-month results of the NVI-III pilot study, according to one expert.

ISTA Pharmaceuticals announced Oct. 16 that it had received FDA approval to market bromfenac ophthalmic solution 0.09% as a once-daily treatment for inflammation and reduction of ocular pain in patients who had undergone cataract surgery.